Hoshizaki Corporation (HSHIF)
Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
At close: 11:10AM EDT
| Previous close | 64.00 |
| Open | 64.00 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 64.00 - 64.00 |
| 52-week range | 32.00 - 93.75 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 9.271B |
| Beta (5Y monthly) | 0.75 |
| PE ratio (TTM) | 58.18 |
| EPS (TTM) | 1.10 |
| Earnings date | N/A |
| Forward dividend & yield | 0.70 (2.19%) |
| Ex-dividend date | 29 June 2023 |
| 1y target est | N/A |
- GlobeNewswire
Taysha Gene Therapies Receives Orphan Drug Designation from the European Commission for TSHA-120 for the Treatment of Giant Axon Neuropathy (GAN)
Clinical efficacy data for TSHA-120 provide quantitative evidence of long-term durability across all therapeutic dose cohorts with a 10-point improvement in mean change in MFM32 by Year 3 compared to estimated natural history decline of 24 points Biopsy data in five of six patient samples analyzed to date confirmed active regeneration of nerve fibers following treatment with TSHA-120 53 patient-years of clinical data support favorable safety and tolerability profile of TSHA-120 Estimated address
© 2023 Yahoo. All rights reserved.
